Paris, France, Cambridge (Massachusetts, USA), June 5, 2022 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a stage clinic specializing in the development of treatments aimed at slowing the degenerative processes associated with aging and improving the functional outcomes of patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces today today that it participates in the International Convention of the Biotechnology Innovation Organization (BIO) which is being held in Boston from June 5 to 8, 2023 and brings together several thousand world leaders in biotechnology and the pharmaceutical industry.
Biophytis’ participation in BIO is part of the Company’s strategy to forge partnerships with global or regional players for its main drug candidates developed in age-related diseases, in particular sarcopenia, and in rare neuromuscular diseases, especially Duchenne muscular dystrophy.